Common use of Financial Consideration Clause in Contracts

Financial Consideration. The Sponsor agrees to pay the VHIR, as the entity that manages the HUVH research, the amounts established in the Financial Budget in accordance with the instalments established in this Annex I. Any modification of the budget contained in the Financial Budget must be mutually agreed to by the Parties. The amounts indicated in the Financial Budget will accrue VAT corresponding to the Sponsor's account, if applicable, according to current regulations The Sponsor will pay the VHIR the amount corresponding to the sections “Internal Costs - Tests”, “Internal Costs - Visits” and “Other Costs” specified in the Financial Budget (hereinafter, “Costs”). The Sponsor will pay the amount resulting from applying the percentages established in section D, section E and section F of the Financial Budget, on the total basis of the Costs. This amount is intended to meet the foundational purposes of VHIR (promotion of Biomedical Research, Innovation and Teaching of HUVH) or medication management of the Pharmacy Service. The billing will take into account the number of patients included or recruited in the Trial, independently if they complete the treatment or if they do not complete it, so that the amount to be paid by the Sponsor will be proportionally modified to always guarantee compensation for total services actually provided. In the event that remote monitoring is carried out, in accordance with the provisions of Clause 14 and in order to cover the additional costs incurred by VHIR for the management of remote monitoring, the Sponsor shall pay VHIR an amount of €50 plus VAT per day of monitoring within the framework of this Trial. Compensation will be based as set forth in the patient visit log and case application forms ("CRF"). The Sponsor will pay the VHIR the extraordinary costs referred to in section G of the Financial Budget. The percentage established in section H, 10%, will be additionally applied to these costs, in order to adequately cover the management costs of said items incurred by the VHIR. The Sponsor shall pay the VHIR the amount of €1,500 for administrative, start-up and trial management costs. This initial single payment will also be reflected in the Financial Budget in this Annex I, will be billed with the signing of the Contract without being conditioned to the effective realization of the Test or to the approval of it by the ECRm or the AEMPS. The travel, accommodation and subsistence expenses of the patients will be managed through a service company designated by the Sponsor, and the HUVH and VHIR will be exempt from any type of management and / or processing of patient reimbursements during the Trial.

Financial Consideration. The Sponsor agrees to pay to the VHIO as the entity that manages the research process of the Oncology, Medical Hematology and Radiation Oncology Service of the HUVH and to the VHIR, as the entity that manages managing the HUVH researchresearch of the HUVH, the amounts established in the Financial Budget Economic Report in accordance with the instalments established in provisions of this Annex I. Annex. Any modification of the budget contained in the Financial Budget must be mutually agreed to by the Parties. The amounts indicated in the Financial Budget will accrue VAT corresponding to the Sponsor's account, if applicable, according to current regulations The Sponsor will pay the to VHIR the amount corresponding to the sections “Internal Costs - Tests”E, “Internal Costs - Visits” F and “Other Costs” specified in the Financial Budget (hereinafter, “Costs”). The Sponsor will pay the amount resulting from applying the percentages established in section D, section E and section F H of the Financial Budget, on the total basis of the Costs. This amount is intended Economic Report in order to meet satisfy the foundational purposes of VHIR (promotion of Biomedical Research, Innovation and Teaching of HUVH) or medication management ). The Sponsor will pay the VHIO the amount corresponding to the remaining sections of the Pharmacy ServiceEconomic Report in order to meet the costs of the Trial. The billing will take into account the number of patients included or recruited in the Trial, independently if they complete the treatment or if they do not complete it, so that the amount to be paid by the Sponsor will be proportionally modified to always guarantee compensation for total services actually provided. In the event that remote monitoring is carried out, in accordance with the provisions of Clause 14 and in order to cover the additional costs incurred by VHIR VHIO for the management of remote monitoring, the Sponsor shall pay VHIR VHIO an amount of €50 plus VAT per day of monitoring within the framework of this Trial. Compensation will be based as set forth in the patient visit log and case application forms ("CRF"). The In the exceptional case that the Sponsor will pay does not provide the VHIR Product directly (being this possibility previously accepted by HUVH and VHIO), the extraordinary costs referred to in section G payment of the Financial Budgetsame will be governed by the following conditions: VHIO will invoice the medication according to the official RRP of each unit (each vial/bottle/box) at the time of reimbursement, adding to the same an amount of €150 per invoice as Pharmacy Service costs. The A percentage established in section H, of 10%, % will be additionally applied to these costs, in order to adequately cover the management costs of said items incurred by the VHIRVHIO for these items. The Sponsor shall pay the VHIR the amount of €1,500 for administrative, start-up and trial management costs. This The Sponsor will pay VHIO the amount of €1,500 for the start-up costs of the Study in the Oncology/Hematology Department and an amount of €1,000 for the start-up of the Trial by the Pharmacy Department. These initial single payment one-time payments will also be reflected in the Financial Budget Report attached in this Annex IAnnex, and will be billed invoiced with the signing of the Contract without being conditioned to the effective realization performance of the Test Trial or to the its approval of it by the ECRm or the AEMPS. The travel, accommodation and subsistence expenses of the patients will be managed through a service company designated by the Sponsor. The HUVH, VHIR and the HUVH and VHIR VHIO will be exempt from any type of management and / or processing of patient reimbursements during the Trial. In case of audit of the Trial by the Sponsor, the Sponsor shall pay VHIO the amount of 500 € per day for each day of the audit visit to compensate the costs incurred by the VHIO in the preparation, conduct and subsequent follow-up of the audit. This amount will not be applicable to regulatory agency inspections.